Announcements Trials
Browse Landscape

Phase

Phase 1/2 9Phase 1 6Phase 2 5Phase 3 4Phase EARLY_PHASE1 2Phase 4 1

Status

Active not recruiting 3Recruiting 2

Sponsor Class

OTHER 16INDUSTRY 5

Study Type

Interventional 5

Sponsor

Cancer Type

Genitourinary 5

Conditions

Carcinoma, Non-Small-Cell Lung 687Breast Neoplasms 585Neoplasms 468Colorectal Neoplasms 300Prostatic Neoplasms 263Neoplasm Metastasis 257Melanoma 242Ovarian Neoplasms 228Recurrence 216Lung Neoplasms 203Multiple Myeloma 196Lymphoma, Non-Hodgkin 155Pancreatic Neoplasms 154Leukemia, Myeloid, Acute 142Carcinoma, Hepatocellular 141Stomach Neoplasms 137Lymphoma 131Carcinoma, Renal Cell 128Glioblastoma 118Squamous Cell Carcinoma of Head and Neck 113Head and Neck Neoplasms 113Lymphoma, Follicular 106Leukemia, Lymphocytic, Chronic, B-Cell 99Small Cell Lung Carcinoma 96Lymphoma, Large B-Cell, Diffuse 96Leukemia 96Brain Neoplasms 91Carcinoma 82Uterine Cervical Neoplasms 77Triple Negative Breast Neoplasms 73

Interventions

olaparib 1enzalutamide 1abiraterone 1Prednisolone 1Androgen Antagonists 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × Metastatic Castration-resistant Prostate Cancer × Clear all
NCT06228053 2026-06-02

SYNERGY-201

Syntrix Biosystems, Inc.

Phase 2 Recruiting
53 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06533644 2026-05-18

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

Syncromune, Inc.

Phase 2 Recruiting
91 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06909825 2026-05-06

FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Fusion Pharmaceuticals Inc.

Phase 2 Active not recruiting
85 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT06402331 2026-04-08

AlphaBreak

Fusion Pharmaceuticals Inc.

Phase 2 Active not recruiting
110 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡